湖南裕能(301358.SZ):擬在馬來西亞成立有關公司 以投建年產9萬噸鋰電池正極材料項目
格隆匯7月22日丨湖南裕能(301358.SZ)公佈,公司於2025年7月22日召開第二屆董事會第十四次會議,審議通過《關於在馬來西亞投資併成立有關公司的議案》,同意公司在新加坡新設立投資公司,並由投資公司在馬來西亞設立項目公司,通過項目公司投資建設年產9萬噸鋰電池正極材料項目。項目總投資約5.6億馬來西亞林吉特,約合人民幣9.5億元(最終投資金額以項目建設實際投入爲準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.